LCM
DAWN

Laurion Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Laurion Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-171,887
Closed -$2.37M – 374
2024
Q2 		$2.37M Buy
171,887
+6,904
+4% +$101K 0.03% 209
2024
Q1 		$2.73M Hold
164,983
– – 0.02% 315
2023
Q4 		$2.41M Buy
+164,983
New +$2M 0.02% 283
2023
Q3 		– Sell
-10,134
Closed -$121K – 522
2023
Q2 		$121K Sell
10,134
-4,866
-32% -$63.6K ﹤0.01% 508
2023
Q1 		$201K Hold
15,000
– – ﹤0.01% 386
2022
Q4 		$323K Buy
15,000
+763
+5% +$15.7K ﹤0.01% 367
2022
Q3 		$285K Sell
14,237
-763
-5% -$16.2K ﹤0.01% 424
2022
Q2 		$269K Sell
15,000
-76,239
-84% -$787K ﹤0.01% 376
2022
Q1 		$905K Buy
+91,239
New +$1.21M 0.01% 256

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Laurion Capital Management's DAWN Position: Q3 2024 in Review

Laurion Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q3 2024, closing a stake of 171,887 shares — an estimated $2.37M sold.

Laurion Capital Management first reported a position in DAWN in Q1 2022 and held it in 9 quarters. The position peaked at $2.73M in Q1 2024. 166 funds tracked by Wall St. Rank hold DAWN as of Q3 2024.

  • Laurion Capital Management reported no remaining Day One Biopharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Laurion Capital Management sold 171,887 Day One Biopharmaceuticals shares in Q3 2024, an estimated $2.37M.
  • Laurion Capital Management first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 9 quarters.
  • Laurion Capital Management's Day One Biopharmaceuticals position peaked at $2.73M in Q1 2024.
  • 166 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2024.

Based on Laurion Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.